S-540956 |
|
Vaxjo ID |
190 |
|
Vaccine Adjuvant Name |
S-540956 |
|
Adjuvant VO ID |
VO_0006104
|
|
Description |
oligonucleotide vaccine adjuvant that is a TLR9-agonistic adjuant containing a CpG oligonucleotide annealed to a complementary strand with an amphiphilic chain unit, acts as a potent cancer vaccine adjuvant by targeting draining lymph nodes, induces Th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
Japan (Shionogi &Co., Ltd) |
|
Host Species for Testing |
3 |
|
Second Host Species for Testing |
7 |
|
Components |
f B-type CpG ODN2006 (also known as CpG7909), annealed to its complementary sequence oligodeoxynucleotide (ODN) conjugated to a lipid |
|
Preparation |
solid-phase synthesis using a typical phosphoramidite method |
|
Function |
innate immune activation, induces CD8T cells |
| References |
(Takeuchi, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=91]
Gill, 1971: Gill DG. The British National Health Service: professional determinants of administrative structure. International journal of health services : planning, administration, evaluation. 1971; 1(4); 342-353. [PubMed: 5003132].
|
